Evaluation of ceftazidime/avibactam for treatment of carbapenemase-producing carbapenem-resistant Enterobacterales with OXA-48 and/or NDM genes with or without combination therapy.
Journal
JAC-antimicrobial resistance
ISSN: 2632-1823
Titre abrégé: JAC Antimicrob Resist
Pays: England
ID NLM: 101765283
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
23
05
2022
accepted:
08
09
2022
entrez:
14
10
2022
pubmed:
15
10
2022
medline:
15
10
2022
Statut:
epublish
Résumé
Carbapenem-resistant Enterobacterales (CRE) is an urgent public health threat of significant global concern. Few observational studies have evaluated the clinical outcomes for treatment of CRE harbouring OXA-48 or NDM genes with ceftazidime/avibactam. Previous findings showed lower 30 day mortality with ceftazidime/avibactam ranges between 8.3% and 22%. This single-centre retrospective cohort study included adult patients aged ≥18 years admitted to King Abdulaziz Medical City (KAMC) who had received ceftazidime/avibactam for at least 72 h for infections caused by CRE with genes encoding for carbapenemase production (CP-CRE). A total of 211 patients, mostly male (57%), having CP-CRE infections treated with ceftazidime/avibactam were included, with an average age of 62 years. More than 50% of patients were critically ill, for which 46% received invasive ventilation and 36% were on inotropes. The most frequent infectious disease was hospital/ventilator-acquired pneumonia with This was the largest study that evaluated clinical outcomes associate with CP-CRE harbouring OXA-48 gene infections treated with ceftazidime/avibactam. Clinical cure and 30 day mortality were consistent with those of previous studies. Findings suggested that combination therapy with ceftazidime/avibactam had no direct impact on clinical outcomes for CP-CRE with OXA-48.
Sections du résumé
Background
UNASSIGNED
Carbapenem-resistant Enterobacterales (CRE) is an urgent public health threat of significant global concern. Few observational studies have evaluated the clinical outcomes for treatment of CRE harbouring OXA-48 or NDM genes with ceftazidime/avibactam. Previous findings showed lower 30 day mortality with ceftazidime/avibactam ranges between 8.3% and 22%.
Method
UNASSIGNED
This single-centre retrospective cohort study included adult patients aged ≥18 years admitted to King Abdulaziz Medical City (KAMC) who had received ceftazidime/avibactam for at least 72 h for infections caused by CRE with genes encoding for carbapenemase production (CP-CRE).
Results
UNASSIGNED
A total of 211 patients, mostly male (57%), having CP-CRE infections treated with ceftazidime/avibactam were included, with an average age of 62 years. More than 50% of patients were critically ill, for which 46% received invasive ventilation and 36% were on inotropes. The most frequent infectious disease was hospital/ventilator-acquired pneumonia with
Conclusions
UNASSIGNED
This was the largest study that evaluated clinical outcomes associate with CP-CRE harbouring OXA-48 gene infections treated with ceftazidime/avibactam. Clinical cure and 30 day mortality were consistent with those of previous studies. Findings suggested that combination therapy with ceftazidime/avibactam had no direct impact on clinical outcomes for CP-CRE with OXA-48.
Identifiants
pubmed: 36237571
doi: 10.1093/jacamr/dlac104
pii: dlac104
pmc: PMC9552550
doi:
Types de publication
Journal Article
Langues
eng
Pagination
dlac104Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.
Références
Expert Opin Drug Metab Toxicol. 2019 Feb;15(2):133-149
pubmed: 30626244
Emerg Infect Dis. 2014 Jul;20(7):1235-6
pubmed: 24960464
J Glob Antimicrob Resist. 2020 Dec;23:26-32
pubmed: 32721564
BMC Infect Dis. 2019 Sep 4;19(1):772
pubmed: 31484510
Am J Hematol. 2016 Nov;91(11):1076-1081
pubmed: 27428072
Infect Drug Resist. 2022 Jan 23;15:211-221
pubmed: 35125877
Int J Antimicrob Agents. 2019 Apr;53(4):520-524
pubmed: 30471403
Antibiotics (Basel). 2020 Jul 07;9(7):
pubmed: 32645986
Clin Infect Dis. 2021 Jun 1;72(11):1871-1878
pubmed: 32427286
J Antimicrob Chemother. 2018 Nov 1;73(11):3170-3175
pubmed: 30099490
Int J Infect Dis. 2021 Aug;109:1-7
pubmed: 34091006
Medicine (Baltimore). 2021 Apr 9;100(14):e24880
pubmed: 33832068
Ann Saudi Med. 2021 Mar-Apr;41(2):63-70
pubmed: 33818149
Virulence. 2017 May 19;8(4):460-469
pubmed: 27593176